Home » Topics » BioWorld Science

BioWorld Science
RSS

New phase Ib/IIa trial studies RTB-101 for Parkinson's disease

April 3, 2019

ProQR Therapeutics discloses new HTT-targeting antisense oligonucleotides

April 3, 2019

Phase I data reported for shERPA agent TTC-352

April 3, 2019

Mologen synthesizes new TLR9 agonists

April 3, 2019

Aldeyra initiates phase III trial of reproxalap in dry eye disease

April 3, 2019

FDA clears Cellectis to begin phase I trial of UCARTCS1 in multiple myeloma

April 3, 2019

Altor BioScience identifies new fusion proteins for treatment of cancer

April 3, 2019

Alector initiates first-in-human study of AL-003 for Alzheimer's disease

April 3, 2019

Stoke Therapeutics divulges new antisense oligomers

April 3, 2019

Dragonfly Therapeutics patents NKG2D-binding proteins for cancer

April 3, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...